China NMPA grants marketing approval for Innovent Biologics' Tyvyt, a CTLA-4 monoclonal antibody: San Francisco Saturday, December 27, 2025, 16:00 Hrs [IST] Innovent Biologics Inc ...
The Moscow Times on MSN
St. Petersburg opens first 2 stations on new metro line
The city of St. Petersburg on Friday opened two metro stations that form the initial segment of a new metro line. The ...
The Hundred Line's developer almost went bankrupt making it, but the quality and success of the game fills me with hope.
Zacks Investment Research on MSN
4 drug, biotech stocks rising more than 50% in 2025 with room to grow
The drug and biotech sector witnessed a see-saw performance in 2025. After a weak show for most of the year, the sector ...
The group talked about season two of the Paramount+ show, which stars Billy Bob Thornton and was co-created by Taylor Sheridan.
No one's crossed the finishing line yet, but drug developer Nyrada is leading the Great Biotech Regatta of 2025 with close to ...
The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, ...
The company plans to announce Phase 1b interim data by mid-2026, and the TENACITY-01 study is expected to be completed by late 2028. This timing enables progression to Phase 2 evaluation following ...
In the last Fierce Pharma Asia weekly news roundup of 2025, Daiichi Sankyo scored a key FDA approval for ...
Early Thursday, Takeda revealed top-line data for two pivotal phase 3 trials of its next-gen, highly selective oral tyrosine ...
Eli Lilly and Co. disclosed positive top-line data from the phase III Attain-Maintain trial with orforglipron, a once-daily oral small-molecule GLP-1 receptor agonist. The compound was tested for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results